2016
DOI: 10.1007/978-3-319-29185-7_2
|View full text |Cite
|
Sign up to set email alerts
|

Living Donors for Fulminant Hepatic Failure in Children

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 61 publications
0
1
0
Order By: Relevance
“…The right to withdraw from a XTx clinical trial may not be the only ethical issue that an IRB will face. Questions regarding risk‐benefit assessment, 28 patient selection criteria that are equitable, 29 and how to achieve true voluntary consent may arise 30,31 . Furthermore, one risk that may need to be assessed on an ongoing basis alongside the regular renewal of the clinical trial (on an annual basis or the timeline required by the institution) would be adherence to transplantation medicines, for example, immunosuppressive drugs.…”
Section: Ethical Issues Presented By Xenotransplantationmentioning
confidence: 99%
“…The right to withdraw from a XTx clinical trial may not be the only ethical issue that an IRB will face. Questions regarding risk‐benefit assessment, 28 patient selection criteria that are equitable, 29 and how to achieve true voluntary consent may arise 30,31 . Furthermore, one risk that may need to be assessed on an ongoing basis alongside the regular renewal of the clinical trial (on an annual basis or the timeline required by the institution) would be adherence to transplantation medicines, for example, immunosuppressive drugs.…”
Section: Ethical Issues Presented By Xenotransplantationmentioning
confidence: 99%